GSK to acquire human Genome Sciences for US$14.25 per share in cash
GlaxoSmithKline plc and Human Genome Sciences recently announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
GlaxoSmithKline plc today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.